Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung Carcinoma

Authors

  • Elaine A. Dunlop Ph.D.,

    Corresponding author
    1. Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom
    • Haematology Research Laboratory, University Floor, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, United Kingdom. Telephone: 44-2890-263718; Fax: 44-2890-263927
    Search for more papers by this author
  • Alexander P. Maxwell,

    1. Nephrology Research Group, Queen's University, Belfast, United Kingdom
    Search for more papers by this author
  • Terence R.J. Lappin

    1. Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom
    Search for more papers by this author

Abstract

Recent evidence confirms the presence of erythropoietin receptors on a variety of cancer cells. This has raised concerns about the use of erythropoiesis-stimulating agents in the treatment of cancer-related anemia. Having previously identified expression of functional erythropoietin receptors in a non-small cell lung carcinoma cell line, H838, which activated key signaling pathways in response to erythropoietin stimulation, we now demonstrate impaired downregulation of the erythropoietin receptor in these tumor cells. The erythropoietin receptor is not ubiquitinated following erythropoietin stimulation in this cancer cell line, and there is no turnover of the receptor in either unstimulated or stimulated cells. Compounding this blunted response is impaired SOCS3 induction downstream of erythropoietin stimulation and an extremely delayed SOCS1 response. If this finding in non-small cell lung carcinoma is a widespread phenomenon, then impaired erythropoietin receptor downregulation and degradation in tumor cells has clinical implications for those patients receiving erythropoiesis-stimulating agents for cancer-related anemia.

Ancillary